# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Psyence Biomed launches Phase IIb trials for psilocybin in palliative care and Alcohol Use Disorder, bolstering its clinical pi...
https://www.globenewswire.com/en/news-release/2024/09/16/2946746/0/en/Psyence-Group-s-NASDAQ-Listed-Associate-Psyence-Biomedica...
Psyence Biomed initiates a Phase IIb psilocybin trial in Australia to explore its potential as a treatment for Adjustment Disor...
As consideration for the Proposed Acquisition, Psyence Biomed will issue $500,000 of the Company's common shares upon closi...
Psyence Biomedical shares are trading lower by 34% during Wednesday's session. The company announced an exclusive licensing...